



10/069 062

coll

PATENT  
ATTORNEY DOCKET NO.: 056291-5073

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of: )  
ROSAMOND et al. )  
U.S. Patent No: 7,001,757 )  
Issued: February 21, 2006 )  
FOR: PROTEIN )

Date: October 17, 2006

**REQUEST FOR A CERTIFICATE OF CORRECTION**

Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Service Window, Mail Stop POST ISSUE  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

**Certificate**  
**OCT 19 2006**  
**of Correction**

Sir:

Attached hereto is a PTO/SB/44 requesting certain amendments to the issued patent referenced above. Throughout prosecution it was noted the first inventor's name was misspelled, and was again misspelled on the official Letters Patent.

The claims are hereby amended as intended by an Examiner's Amendment contained in the Notice of Allowance. The amendments were not completed as the Examiner intended and correction is respectfully requested through issuance of a Certificate of Correction.

No fees are believed due; however, the Patent Office may charge any fees required in order to complete and issue this Certificate to Morgan Lewis & Bockius LLP Deposit Account No. 50-0310.

Respectfully Submitted,  
Morgan Lewis & Bockius LLP

Date: October 17, 2006  
Morgan Lewis & Bockius LLP  
Customer No. 09629  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
Tel. No.: 202-739-3000

By:

Donald J. Bird  
Registration No. 25,323  
Tel. No.: (202) 739-5320  
Fax No.: (202) 739-3001

**OCT 19 2006**

## UNITED STATES PATENT AND TRADEMARK OFFICE

## CERTIFICATE OF CORRECTION

PATENT NO : 7,001,757

DATED : February 21, 2006

INVENTOR(S) : PROTEIN

It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

On the masthead page:

Please correct the first inventor's name to read: John David ROSAMOND.

In columns 23 and 24 amend the claims to read as follows:

2 The purified polypeptide having Phosphomevalonate kinase (PMK) activity of claim 1 wherein the polypeptide is isolated from *Candida albicans*.

3. A method to identify compounds that inhibit Phosphomevalonate kinase (PMK) activity, said method comprising the steps of contacting a test compound with the polypeptide of claim 1, in the presence of appropriate assay components and under conditions effective to detect inhibition of the PMK activity.

4. A diagnostic kit for detecting the presence of *Candida albicans* comprising an antibody that selectively binds to the polypeptide of claim 1.

MAILING ADDRESS OF SENDER: Donald L. Bird  
Morgan, Lewis & Bockius LLP  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004

PATENT NO. 7,001,757

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

OCT 19 2006